WINTON GROUP Ltd Sells 270,739 Shares of Puma Biotechnology, Inc. (NASDAQ:PBYI)

WINTON GROUP Ltd trimmed its stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) by 87.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 38,241 shares of the biopharmaceutical company’s stock after selling 270,739 shares during the period. WINTON GROUP Ltd’s holdings in Puma Biotechnology were worth $117,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of the stock. LPL Financial LLC raised its holdings in Puma Biotechnology by 23.6% during the 4th quarter. LPL Financial LLC now owns 26,567 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 5,080 shares during the last quarter. Prudential Financial Inc. increased its position in shares of Puma Biotechnology by 5.8% during the fourth quarter. Prudential Financial Inc. now owns 106,285 shares of the biopharmaceutical company’s stock worth $324,000 after buying an additional 5,800 shares during the period. Gateway Wealth Partners LLC bought a new position in Puma Biotechnology during the fourth quarter worth $31,000. SG Americas Securities LLC lifted its holdings in Puma Biotechnology by 83.9% in the fourth quarter. SG Americas Securities LLC now owns 24,668 shares of the biopharmaceutical company’s stock valued at $75,000 after buying an additional 11,252 shares during the period. Finally, Franklin Resources Inc. bought a new stake in Puma Biotechnology during the third quarter valued at $41,000. 61.29% of the stock is owned by institutional investors.

Insider Buying and Selling at Puma Biotechnology

In related news, CEO Alan H. Auerbach sold 33,841 shares of the company’s stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $106,599.15. Following the sale, the chief executive officer now owns 7,029,674 shares in the company, valued at $22,143,473.10. This represents a 0.48 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, insider Jeffrey Jerome Ludwig sold 9,437 shares of Puma Biotechnology stock in a transaction dated Thursday, January 2nd. The shares were sold at an average price of $3.15, for a total value of $29,726.55. Following the transaction, the insider now owns 108,951 shares of the company’s stock, valued at $343,195.65. This trade represents a 7.97 % decrease in their position. The disclosure for this sale can be found here. Insiders own 23.70% of the company’s stock.

Puma Biotechnology Stock Down 5.7 %

Shares of NASDAQ PBYI opened at $2.96 on Tuesday. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The firm has a market cap of $146.85 million, a PE ratio of 6.17 and a beta of 1.33. The company’s fifty day simple moving average is $3.10 and its 200 day simple moving average is $2.98. Puma Biotechnology, Inc. has a 12-month low of $2.23 and a 12-month high of $6.06.

Puma Biotechnology (NASDAQ:PBYI) last released its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported $0.39 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.10 by $0.29. Puma Biotechnology had a net margin of 9.56% and a return on equity of 41.60%. The company had revenue of $59.10 million for the quarter, compared to analysts’ expectations of $52.50 million. As a group, sell-side analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on PBYI shares. HC Wainwright reissued a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Friday, February 28th. StockNews.com lowered Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a research note on Saturday, March 8th.

Puma Biotechnology Company Profile

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.